In this study, we profile the responses of human BRAFV600E/D melanoma lines to RAF and MEK inhibitors to: (i) characterize variability in adaptation with time, dose, and genotype, (ii) discover new adaptive mechanisms, and (iii) compare phenotypes of adaptation at single-cell and population levels. The gene discussed is MAP2K7; the disease is melanoma.